Klopidogrel etkileşimleri

CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.7) , Drug Interactions (7.2) , and Clinical Pharmacology (12.2) ]. (Abrositinib etiketi, Kontrendikasyonlar)

…hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (Apiksaban etiketi, Kutulu uyarı)

Antiplatelets: ticagrelor ↑ ticagrelor Coadministration with ticagrelor is not recommended due to potential increase in the risk of dyspnea, bleeding and other adverse events associated with ticagrelor. clopidogrel ↓ clopidogrel active metabolite Coadministration of REYATAZ (with or without ritonavir) and clopidogrel is not recommended. (Atazanavir etiketi, İlaç etkileşimleri)

Coadministration of bupropion hydrochloride extended-release tablets (XL) with ticlopidine or clopidogrel is not recommended (7.1). (Bupropion etiketi, İlaç etkileşimleri)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (Dabigatran etiketi, Kutulu uyarı)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (Edoksaban etiketi, Kutulu uyarı)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

Antiplatelets: ticagrelor ↑ ticagrelor Coadminstration with ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Coadministration with clopidogrel is not recommended due to protential reduction of the antiplatelet activity of clopidogrel. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

…hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between… (Enoksaparin etiketi, Kutulu uyarı)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (Ferrik sitrat etiketi, İlaç etkileşimleri)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity or spinal surgery • Optimal timing between… (Fondaparinuks etiketi, Kutulu uyarı)

Anticoagulants and Antiplatelets Ticagrelor Contraindicated during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

Clopidogrel: Do not administer during KENGREAL infusion. (Kangrelor etiketi, İlaç etkileşimleri)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

Cardiovascular agents aliskiren, ticagrelor, vorapaxar clopidogrel ↑ aliskiren ↑ ticagrelor ↑ vorapaxar ↓ clopidogrel active metabolite Avoid concomitant use with PAXLOVID. cilostazol ↑ cilostazol Dosage adjustment of cilostazol is recommended. (Nirmatrelvir ve ritonavir etiketi, İlaç etkileşimleri)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

…TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Effient (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). (Prasugrel etiketi, Kontrendikasyonlar)

Avoid concomitant use of repaglinide with Plavix. (Klopidogrel etiketi, İlaç etkileşimleri)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Klopidogrel etiketi, Uyarılar ve önlemler)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (Rivaroksaban etiketi, Kutulu uyarı)

Celecoxib 100 mg twice daily was non-inferior to naproxen 375 to 500 mg twice daily and ibuprofen 600 to 800 mg three times daily for the composite endpoint of the Antiplatelet Trialists' Collaboration (APTC), which consists of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, and non-fatal stroke [ see Clinical Studies (14.5)… (Selekoksib etiketi, Uyarılar ve önlemler)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

WARNING: BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). (Tikagrelor etiketi, Kutulu uyarı)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (Klopidogrel etiketi, Uyarılar ve önlemler)

Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplaz etiketi, İlaç etkileşimleri)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Anagrelid etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

E vitamini trombosit agregasyonunu ve K vitaminine bağımlı pıhtılaşmayı inhibe edebilir; bu da antikoagülan ve antitrombosit ilaçlarla birlikte kanama riskini artırır. (NIH Office of Dietary Supplements, Vitamin E)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Epoprostenol etiketi, İlaç etkileşimleri)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiplatelets Ticagrelor Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (Fenitoin etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antiplatelets Ticagrelor Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (Fosfenitoin etiketi, İlaç etkileşimleri)

Ginkgo, antikoagülan veya antitrombosit ilaçlarla birlikte alındığında kanama riskini artırabilir. (NCCIH, Ginkgo)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (İkosapent etil etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Anticoagulants and Antiplatelet Drugs rivaroxaban cilostazol, coumarins, dabigatran Cilostazol: Concomitant administration of single doses of cilostazol 100 mg and ketoconazole 400 mg approximately doubled cilostazol concentrations and altered (increase/decrease) the concentrations of the active metabolites of cilostazol. (Ketokonazol etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. (Misoprostol etiketi, İlaç etkileşimleri)

Consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring coadministration of morphine or other opioid agonists. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Concomitant Treatment with CYP2B6 Inhibitors (e.g., ticlopidine or clopidogrel) can increase bupropion exposure. (Naltrekson ve bupropion etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (Pentoksifilin etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Should serious bleeding that is not controlled by local pressure occur, discontinue any concomitant heparin or antiplatelet agents immediately and treat appropriately. (Tenekteplaz etiketi, Uyarılar ve önlemler)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (Klopidogrel etiketi, İlaç etkileşimleri)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Trazodon etiketi, Uyarılar ve önlemler)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (Klopidogrel etiketi, İlaç etkileşimleri)

• Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (Vortioksetin etiketi, Uyarılar ve önlemler)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

Omega-3 takviyeleri kanama zamanını hafifçe uzatabilir; varfarin gibi antikoagülanlarla birlikte kullanım izlem gerektirir, ancak klinik açıdan anlamlı kanama tutarlı biçimde gösterilmemiştir. (NIH Office of Dietary Supplements, Omega-3 Fatty Acids)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

If possible, assess the presence of drug-dependent antiplatelet antibodies. (Etosüksimid etiketi, Uyarılar)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (Klopidogrel etiketi, İlaç etkileşimleri)

Sarımsak takviyeleri, varfarin gibi antikoagülanlarla birlikte kanama riskini artırabilir. (NCCIH, Garlic)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZISTA/ritonavir and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZISTA/ritonavir and clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel active metabolite… (Darunavir etiketi, İlaç etkileşimleri)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZCOBIX or PREZCOBIX PED and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZCOBIX or PREZCOBIX PED with clopidogrel is not recommended due to the potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel… (Darunavir ve kobisistat etiketi, İlaç etkileşimleri)

Platelet Aggregation Inhibitors Clopidogrel: No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with nifedipine. (Nifedipin etiketi, İlaç etkileşimleri)